Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.
暂无分享,去创建一个
[1] John P. Moore,et al. Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.
[2] M. Nussenzweig,et al. A mouse model for HIV-1 entry , 2012, Proceedings of the National Academy of Sciences.
[3] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[4] H. Katinger,et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. , 1999, Immunity.
[5] Michael S. Seaman,et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies , 2012, Proceedings of the National Academy of Sciences.
[6] Young Do Kwon,et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. , 2013, Immunity.
[7] Daniel W. Kulp,et al. Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site , 2015, PLoS pathogens.
[8] Huldrych F. Günthard,et al. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies , 2011, The Journal of experimental medicine.
[9] Paul W. H. I. Parren,et al. Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.
[10] B. Korber,et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection , 2014, AIDS.
[11] William R. Schief,et al. Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies , 2015, Nature Communications.
[12] John P. Moore,et al. A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype B env Gene , 2015, Journal of Virology.
[13] Paul W. H. I. Parren,et al. Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120 , 2003, Journal of Virology.
[14] D R Burton,et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.
[15] J. Mascola,et al. Anti-HIV B Cell Lines as Candidate Vaccine Biosensors , 2012, The Journal of Immunology.
[16] H. Liao,et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance , 2009, Proceedings of the National Academy of Sciences.
[17] Gwo-Yu Chuang,et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-120 interface , 2014, Nature.
[18] Pascal Poignard,et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques , 2009, Nature Medicine.
[19] J. Ruysschaert,et al. The convertases furin and PC1 can both cleave the human immunodeficiency virus (HIV)-1 envelope glycoprotein gp160 into gp120 (HIV-1 SU) and gp41 (HIV-I TM). , 1994, The Journal of biological chemistry.
[20] H. Liao,et al. Induction of HIV-1 Broad Neutralizing Antibodies in 2F5 Knock-in Mice: Selection against Membrane Proximal External Region–Associated Autoreactivity Limits T-Dependent Responses , 2013, The Journal of Immunology.
[21] Tongqing Zhou,et al. PGV04, an HIV-1 gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4 , 2012, Journal of Virology.
[22] Ian A Wilson,et al. Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. , 2015, Cell reports.
[23] Antonio Lanzavecchia,et al. Broadly neutralizing antiviral antibodies. , 2013, Annual review of immunology.
[24] John P. Moore,et al. Structure of 2G12 Fab2 in Complex with Soluble and Fully Glycosylated HIV-1 Env by Negative-Stain Single-Particle Electron Microscopy , 2014, Journal of Virology.
[25] Tongqing Zhou,et al. Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.
[26] Maxim N. Artyomov,et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation , 2010, Nature.
[27] M. Nussenzweig,et al. Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity , 2014, Cell.
[28] M. Nussenzweig,et al. Antibody and Antiretroviral Preexposure Prophylaxis Prevent Cervicovaginal HIV-1 Infection in a Transgenic Mouse Model , 2013, Journal of Virology.
[29] D. Burton,et al. Fc receptor but not complement binding is important in antibody protection against HIV , 2007, Nature.
[30] John P. Moore,et al. Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 , 2002, Journal of Virology.
[31] Young Do Kwon,et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 , 2011, Nature.
[32] Sriram Subramaniam,et al. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures , 2011, Proceedings of the National Academy of Sciences.
[33] R. Zinkernagel,et al. The influence of antigen organization on B cell responsiveness. , 1993, Science.
[34] J. Binley,et al. Nature of Nonfunctional Envelope Proteins on the Surface of Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.
[35] R. Wyatt,et al. Direct Antibody Access to the HIV-1 Membrane-Proximal External Region Positively Correlates with Neutralization Sensitivity , 2011, Journal of Virology.
[36] Alessandro Sette,et al. Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. , 2013, Immunity.
[37] A. Trkola,et al. Different Infectivity of HIV-1 Strains Is Linked to Number of Envelope Trimers Required for Entry , 2015, PLoS pathogens.
[38] D. Burton,et al. Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses , 2012, Science.
[39] D. Burton,et al. Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIVBa-L , 2009, Journal of Virology.
[40] D. Burton,et al. Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies , 2015, PLoS pathogens.
[41] Richard T. Wyatt,et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.
[42] Lynn Morris,et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein , 2012, The Journal of experimental medicine.
[43] Tongqing Zhou,et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.
[44] D. Burton,et al. Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design. , 2015, Immunity.
[45] D. Burton,et al. Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies , 2003, Journal of Virology.
[46] A. Speak,et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery , 2014, Nature Biotechnology.
[47] K. Roskin,et al. HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. , 2014, Cell host & microbe.
[48] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[49] Tongqing Zhou,et al. Structure and immune recognition of trimeric prefusion HIV-1 Env , 2014, Nature.
[50] D. Burton,et al. Protection against High-Dose Highly Pathogenic Mucosal SIV Challenge at Very Low Serum Neutralizing Titers of the Antibody-Like Molecule CD4-IgG2 , 2012, PloS one.
[51] J. Binley,et al. A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure , 2000, Journal of Virology.
[52] Dennis R Burton,et al. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens , 2010, Proceedings of the National Academy of Sciences.
[53] E. Emini,et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[54] R. Desrosiers,et al. Infectivity and Neutralization of Simian Immunodeficiency Virus with FLAG Epitope Insertion in gp120 Variable Loops , 2007, Journal of Virology.
[55] John P. Moore,et al. Structural Evolution of Glycan Recognition by a Family of Potent HIV Antibodies , 2014, Cell.
[56] B. Haynes. New approaches to HIV vaccine development. , 2015, Current opinion in immunology.
[57] Mario Roederer,et al. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.
[58] Scott D Boyd,et al. Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. , 2014, Cell host & microbe.
[59] F. Bibollet-Ruche,et al. Role of V1V2 and Other Human Immunodeficiency Virus Type 1 Envelope Domains in Resistance to Autologous Neutralization during Clade C Infection , 2007, Journal of Virology.
[60] C. Barbas,et al. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1 , 1997, Nature Medicine.
[61] R. Wyatt,et al. Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. , 2015, Cell reports.
[62] Gwo-Yu Chuang,et al. A Short Segment of the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Resistance to V1/V2 Neutralizing Antibodies , 2012, Journal of Virology.
[63] D. Burton,et al. Very Few Substitutions in a Germ Line Antibody Are Required To Initiate Significant Domain Exchange , 2010, Journal of Virology.
[64] William R Schief,et al. Advances in structure-based vaccine design. , 2013, Current opinion in virology.
[65] Han Gao,et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. , 2014, Cell reports.
[66] S. Iida,et al. A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced FcγRIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques , 2012, Journal of Virology.
[67] D. Burton,et al. The Glycan Shield of HIV Is Predominantly Oligomannose Independently of Production System or Viral Clade , 2011, PloS one.
[68] D. Burton,et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo , 2012, Proceedings of the National Academy of Sciences.
[69] D. Burton,et al. The Human Immunodeficiency Virus Type 1 Envelope Spike of Primary Viruses Can Suppress Antibody Access to Variable Regions , 2008, Journal of Virology.
[70] M Anthony Moody,et al. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. , 2006, Human antibodies.
[71] Chaim A. Schramm,et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.
[72] Wayne C Koff,et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. , 2014, Immunity.
[73] M. Nussenzweig,et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia , 2013, Nature.
[74] Peter D. Kwong,et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions , 2014, Science.
[75] Ron Diskin,et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice , 2012, Nature.
[76] D. Leaman,et al. Antibody to gp41 MPER Alters Functional Properties of HIV-1 Env without Complete Neutralization , 2014, PLoS pathogens.
[77] J. Sodroski,et al. Stoichiometry of Envelope Glycoprotein Trimers in the Entry of Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.
[78] David Nemazee,et al. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen , 2015, Science.
[79] Ryan McBride,et al. Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans , 2013, PLoS pathogens.
[80] Daniel W. Kulp,et al. Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice , 2015, Cell.
[81] John P. Moore,et al. Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env , 2015, Nature Communications.
[82] Tahir A. Rizvi,et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.
[83] A. Trkola,et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.
[84] L. Stamatatos. HIV vaccine design: the neutralizing antibody conundrum. , 2012, Current opinion in immunology.
[85] Michael S. Seaman,et al. Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.
[86] B. Vogelstein,et al. Molecular determinants of immunogenicity: the immunon model of immune response. , 1976, Proceedings of the National Academy of Sciences of the United States of America.
[87] Pham Phung,et al. Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.
[88] N. Haigwood,et al. Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies , 2002, Journal of Virology.
[89] John P. Moore,et al. A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies , 2013, PLoS pathogens.
[90] Yan Liu,et al. A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield , 2011, Science.
[91] J. Mascola,et al. Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection , 2015, Journal of Virology.
[92] Vicki C. Ashley,et al. Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia , 2008, Journal of Virology.
[93] Baoshan Zhang,et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.
[94] A. Bartesaghi,et al. Molecular Architectures of Trimeric SIV and HIV-1 Envelope Glycoproteins on Intact Viruses: Strain-Dependent Variation in Quaternary Structure , 2010, PLoS pathogens.
[95] B. Korber,et al. Evolutionary and immunological implications of contemporary HIV-1 variation. , 2001, British medical bulletin.
[96] Yan Liu,et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120 , 2013, Nature Structural &Molecular Biology.
[97] A. Trkola,et al. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1 , 2011, The Journal of experimental medicine.
[98] S. A. Gallo,et al. The HIV Env-mediated fusion reaction. , 2003, Biochimica et biophysica acta.
[99] A. Trkola,et al. Estimating the Stoichiometry of Human Immunodeficiency Virus Entry , 2008, Journal of Virology.
[100] C. Barbas,et al. Protection against HIV‐1 infection in hu‐PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4‐binding site , 1995, AIDS.
[101] Stephen D Fuller,et al. Cryo-Electron Tomographic Structure of an Immunodeficiency Virus Envelope Complex In Situ , 2006, PLoS pathogens.
[102] M. Nussenzweig,et al. Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice , 2014, Cell.
[103] Terri Wrin,et al. Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.
[104] William R. Schief,et al. Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV , 2014, Science Translational Medicine.
[105] I. Wilson,et al. Crystallographic Identification of Lipid as an Integral Component of the Epitope of HIV Broadly Neutralizing Antibody 4E10. , 2016, Immunity.
[106] Michael S. Seaman,et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 , 2015, Nature.
[107] J. Lifson,et al. Distribution and three-dimensional structure of AIDS virus envelope spikes , 2006, Nature.
[108] James E. Crowe,et al. Human Peripheral Blood Antibodies with Long HCDR3s Are Established Primarily at Original Recombination Using a Limited Subset of Germline Genes , 2012, PloS one.
[109] G. Yancopoulos,et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection , 2015, Proceedings of the National Academy of Sciences.
[110] Ping Zhu,et al. Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition , 2003, Science.
[111] G Himmler,et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.
[112] Cinque S. Soto,et al. Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors , 2015, Cell.
[113] Chaim A. Schramm,et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.
[114] D R Burton,et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.
[115] B. Haynes,et al. Rescue of HIV-1 Broad Neutralizing Antibody-Expressing B Cells in 2F5 VH × VL Knockin Mice Reveals Multiple Tolerance Controls , 2011, The Journal of Immunology.
[116] R. Wyatt,et al. B Cells from Knock-in Mice Expressing Broadly Neutralizing HIV Antibody b12 Carry an Innocuous B Cell Receptor Responsive to HIV Vaccine Candidates , 2013, The Journal of Immunology.
[117] C. Cheng‐Mayer,et al. Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.
[118] John P. Moore,et al. Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.
[119] G. Sapiro,et al. Molecular architecture of native HIV-1 gp120 trimers , 2008, Nature.
[120] Feng Gao,et al. Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies , 2014, Cell.
[121] D. Burton,et al. Immune Tolerance Negatively Regulates B Cells in Knock-In Mice Expressing Broadly Neutralizing HIV Antibody 4E10 , 2013, The Journal of Immunology.
[122] D. Burton,et al. Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers , 2009, PLoS pathogens.
[123] Ron Diskin,et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.
[124] Young Do Kwon,et al. Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection , 2015, Cell.
[125] G. Debnath,et al. D-101 HIV-1 neutralizing antibodies induced by native-like envelope trimers , 2016 .
[126] B. Haynes,et al. Polyreactivity and Autoreactivity among HIV-1 Antibodies , 2014, Journal of Virology.
[127] G. Vanham,et al. The N276 Glycosylation Site Is Required for HIV-1 Neutralization by the CD4 Binding Site Specific HJ16 Monoclonal Antibody , 2013, PloS one.
[128] D. Dimitrov,et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens , 2009, Biochemical and Biophysical Research Communications.
[129] A. Trkola,et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies , 2005, Nature Medicine.
[130] P. Klasse. Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. , 2007, Virology.
[131] L. Morris,et al. Virological features associated with the development of broadly neutralizing antibodies to HIV-1. , 2015, Trends in microbiology.
[132] John P. Moore,et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex , 2014, Proceedings of the National Academy of Sciences.
[133] Tongqing Zhou,et al. Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization , 2013, Cell.
[134] Young Do Kwon,et al. Crystal structure , conformational fixation , and entry-related interactions of mature ligand-free HIV-1 Env , 2016 .
[135] Daphne Koller,et al. The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies , 2013, PLoS pathogens.
[136] A. Trkola,et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. , 1994, AIDS research and human retroviruses.
[137] J. Hoxie,et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor , 2014, Science Translational Medicine.
[138] A. Bartesaghi,et al. Pre-fusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy , 2013, Nature Structural &Molecular Biology.
[139] D. Kabat,et al. Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry , 2012, Proceedings of the National Academy of Sciences.
[140] H. Katinger,et al. The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120 , 2002, Journal of Virology.
[141] J. Sodroski,et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.
[142] Young Do Kwon,et al. Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo , 2014, Journal of Virology.
[143] N. Haigwood,et al. Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.
[144] Erin E. H. Tran,et al. Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives , 2012, Proceedings of the National Academy of Sciences.
[145] I. Wilson,et al. Insights into the trimeric HIV-1 envelope glycoprotein structure. , 2015, Trends in biochemical sciences.
[146] R. Wyatt,et al. Well-Ordered Trimeric HIV-1 Subtype B and C Soluble Spike Mimetics Generated by Negative Selection Display Native-like Properties , 2015, PLoS pathogens.
[147] Inhibition of Virus Attachment to CD4+ Target Cells Is a Major Mechanism of T Cell Line–adapted HIV-1 Neutralization , 1997, The Journal of experimental medicine.
[148] J. Mascola,et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.
[149] J. Binley,et al. Enzyme Digests Eliminate Nonfunctional Env from HIV-1 Particle Surfaces, Leaving Native Env Trimers Intact and Viral Infectivity Unaffected , 2011, Journal of Virology.
[150] John R Mascola,et al. Antibody responses to envelope glycoproteins in HIV-1 infection , 2015, Nature Immunology.
[151] A. Ward,et al. Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer , 2016, Science.
[152] Q. Sattentau,et al. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer , 1995, The Journal of experimental medicine.
[153] James C Paulson,et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. , 2014, Immunity.
[154] D. Richman,et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[155] J. Mascola,et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques , 2014, The Journal of experimental medicine.
[156] J. Sodroski,et al. Antibody Binding Is a Dominant Determinant of the Efficiency of Human Immunodeficiency Virus Type 1 Neutralization , 2006, Journal of Virology.
[157] C. Barbas,et al. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. , 1992, Proceedings of the National Academy of Sciences of the United States of America.